Browse News

Found 1,339 articles

• Incyte to Report Fourth Quarter and Year-End 2020 Financial Results

  1/19/2021

  Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021.

• Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia

  1/18/2021

  Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced an agreement with PT Etana Biotechnologies Indonesia (Etana) to out-license BYVASDA®

• Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

  1/12/2021

  Incyte (NASDAQ: INCY) and MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody.

• Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab injection) as First-Line Therapy in Hepatocellular Carcinoma (HCC)

  1/12/2021

  Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the National Medical Products Administration (

• MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

  1/12/2021

  MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody.

• BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies

  1/12/2021

  Clinical and pathological data from clinical trial of the Bria-IMT™ regimen alone or in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the Keystone Symposia, Jan. 25-27, 2021 BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V: BCT ) (OTCQB:BCTXF) ,   a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced br

• INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

  1/11/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the

• Cancer Biological Therapy Market: Top 3 trends driving global industry dynamics

  1/7/2021

  The cancer biological therapy market has witnessed the impact of rising incidences of cancer and a growing number of geriatric populations globally. Older people in the age group of 50 or more possess a high vulnerability to cancer.

• Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804

  12/30/2020

  - Incyte and Cellenkos will evaluate the combination of ruxolitinib (Jakafi ® ) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis - Incyte has an exclusive option to acquire sole rights to CK0804

• Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

  12/28/2020

  Innovent Biologics, Inc. announces that BYVASDA®, a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration of China for the treatment of adult recurrent glioblastoma, which is the third approved indication of BYVASDA® in China.

• Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis

  12/23/2020

  Innovent Biologics, Inc. announces that SULINNO®, a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration of China for two new indications, including the treatment of pediatric plaque psoriasis and non-infectious intermediate uveitis, posterior uveitis and panuveitis in adults who do not respond adequately to corticosteroids, require restraint of corticosteroids, or are not suitable for corticosteroid therapies.

• 

  Clinical Catch-Up: December 14-18

  12/21/2020

  Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.
• 

  Biopharma Update on the Novel Coronavirus: December 15

  12/15/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
• 

  Incyte and Novartis' Jakafi Fails to Reduce COVID-19 Associated Cytokine Storm Complications

  12/14/2020

  Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with COVID-19 associated cytokine storm.
• 

  Clinical Catch-Up: December 7-11

  12/14/2020

  It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates.

• Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

  12/14/2020

  Initial data show that treatment with ruxolitinib plus standard-of-care (SoC) did not prevent complications in patients with COVID-19 associated cytokine storm

• Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine

  12/11/2020

  Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)

• Innovent Announces First Patient Dosed in Phase 2 Pivotal Trial of IBI310 (CTLA-4) combined with TYVYT® (sintilimab injection) for the treatment of second-line or above Advanced Cervical Cancer

  12/11/2020

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first patient has been successfully enrolled a

• Incyte to Present at Investor Conference

  12/9/2020

  Incyte (Nasdaq:INCY) announced today that it will present at the 39 th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solut

• BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®

  12/9/2020

  BriaCell Therapeutics is pleased to announce the presentation results of the clinical studies with its lead product candidate, Bria-IMT™, summarized in a poster session held on December 9 – 11 during the 2020 San Antonio Breast Cancer Symposium